Navigation Links
Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:2/11/2013

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTC: AEMD), announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK:  www.retailinvestorconferences.com> red "register/ watch event now" button

Aethlon Medical's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Aethlon Medical

Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system.  At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers.  For more information, please visit www.aethlonmedical.com.

About The Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system.  In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment.  Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens.  The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA. 

The Aethlon Hemopurifier® and Cancer

In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer.  Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance.  By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
2. Aethlon Medical Discloses CEO Interview
3. Aethlon Medical (AEMD) Note: Extracorporeal Methods to Reduce Inflammation in Sepsis
4. Aethlon Medical To Present Today At The 15th International Conference On Dialysis
5. Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board
6. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
7. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
8. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
9. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
10. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
11. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... SANTA ROSA, Calif. (PRWEB) , ... November 19, 2019 , ... ... time; however growers in the commercial space have been transitioning to powdered nutrients because ... suit as well. Due to the difficulty in combining essential macro and micronutrients, most ...
(Date:11/19/2019)... ... November 18, 2019 , ... San ... on national Cannabidiol (CBD) product sales through a new partnership announced today. This ... non-tetrahydrocannabinol (THC) CBD products. , A selection of Rodkeys branded non-THC CBD products ...
(Date:11/19/2019)... ... , ... Respected Hollywood actor and film director, Laurence Fishburne, ... Fishburne. The program’s central focus is to inform the general public about issues ... aired on the show, a new segment covering TMJD (Temporomandibular Disorder) and the ...
Breaking Medicine Technology:
(Date:11/21/2019)... ... November 21, 2019 , ... Google disclosed ... information and therefore, AllKindsofTherapy.com average session length is two minutes. Treatment ... a therapist is licensed, clinical hours with clients, and types of evidence-based treatments ...
(Date:11/21/2019)... TORONTO (PRWEB) , ... November 21, 2019 , ... ... upcoming live webinar, “Building an effective global supply chain through implementation of ... (3:30pm GMT/UK). , During this live webinar , international logistics specialist, Sharon ...
(Date:11/21/2019)... TWINSBURG, Ohio (PRWEB) , ... ... ... leading electronic health record (EHR) technology partner to North America’s long-term post-acute ... Partner of the Year. The award recognizes the close collaboration between Richter ...
(Date:11/20/2019)... ... November 20, 2019 , ... Promises Behavioral Health, a leading ... clients stay on track with their recovery after initial care. The Rooted alumni program ... cost to their clients. , The Rooted alumni program was created with the ...
(Date:11/19/2019)... ... November 19, 2019 , ... Modern ... Experience Ancient Seas Founder Lisa Hall to discuss their simple, authentic ... mineral-rich products that nourish skin with eighty-four trace minerals. These uniquely formulated products ...
Breaking Medicine News(10 mins):